These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 15031207

  • 1. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis.
    Rusnati M, Camozzi M, Moroni E, Bottazzi B, Peri G, Indraccolo S, Amadori A, Mantovani A, Presta M.
    Blood; 2004 Jul 01; 104(1):92-9. PubMed ID: 15031207
    [Abstract] [Full Text] [Related]

  • 2. Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis.
    Leali D, Inforzato A, Ronca R, Bianchi R, Belleri M, Coltrini D, Di Salle E, Sironi M, Norata GD, Bottazzi B, Garlanda C, Day AJ, Presta M.
    Arterioscler Thromb Vasc Biol; 2012 Mar 01; 32(3):696-703. PubMed ID: 22267482
    [Abstract] [Full Text] [Related]

  • 3. Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide.
    Leali D, Bianchi R, Bugatti A, Nicoli S, Mitola S, Ragona L, Tomaselli S, Gallo G, Catello S, Rivieccio V, Zetta L, Presta M.
    J Cell Mol Med; 2010 Aug 01; 14(8):2109-21. PubMed ID: 19627396
    [Abstract] [Full Text] [Related]

  • 4. Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors.
    Leali D, Alessi P, Coltrini D, Ronca R, Corsini M, Nardo G, Indraccolo S, Presta M.
    Mol Cancer Ther; 2011 Sep 01; 10(9):1600-10. PubMed ID: 21764903
    [Abstract] [Full Text] [Related]

  • 5. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo.
    Camozzi M, Zacchigna S, Rusnati M, Coltrini D, Ramirez-Correa G, Bottazzi B, Mantovani A, Giacca M, Presta M.
    Arterioscler Thromb Vasc Biol; 2005 Sep 01; 25(9):1837-42. PubMed ID: 16020751
    [Abstract] [Full Text] [Related]

  • 6. Fibroblast growth factor-2 antagonist and antiangiogenic activity of long-pentraxin 3-derived synthetic peptides.
    Leali D, Alessi P, Coltrini D, Rusnati M, Zetta L, Presta M.
    Curr Pharm Des; 2009 Sep 01; 15(30):3577-89. PubMed ID: 19860702
    [Abstract] [Full Text] [Related]

  • 7. Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer.
    Ronca R, Alessi P, Coltrini D, Di Salle E, Giacomini A, Leali D, Corsini M, Belleri M, Tobia C, Garlanda C, Bonomi E, Tardanico R, Vermi W, Presta M.
    J Pathol; 2013 Jun 01; 230(2):228-38. PubMed ID: 23424081
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells.
    Ronca R, Di Salle E, Giacomini A, Leali D, Alessi P, Coltrini D, Ravelli C, Matarazzo S, Ribatti D, Vermi W, Presta M.
    Mol Cancer Ther; 2013 Dec 01; 12(12):2760-71. PubMed ID: 24130051
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers.
    Giacomini A, Matarazzo S, Pagano K, Ragona L, Rezzola S, Corsini M, Di Salle E, Presta M, Ronca R.
    Oncotarget; 2015 May 30; 6(15):13790-802. PubMed ID: 25912421
    [Abstract] [Full Text] [Related]

  • 16. Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.
    Presta M, Oreste P, Zoppetti G, Belleri M, Tanghetti E, Leali D, Urbinati C, Bugatti A, Ronca R, Nicoli S, Moroni E, Stabile H, Camozzi M, Hernandez GA, Mitola S, Dell'Era P, Rusnati M, Ribatti D.
    Arterioscler Thromb Vasc Biol; 2005 Jan 30; 25(1):71-6. PubMed ID: 15514208
    [Abstract] [Full Text] [Related]

  • 17. Pentraxin 3 inhibits fibroblast growth factor 2 induced osteoclastogenesis in rheumatoid arthritis.
    Zhao S, Wang Y, Hou L, Wang Y, Xu N, Zhang N.
    Biomed Pharmacother; 2020 Nov 30; 131():110628. PubMed ID: 32890968
    [Abstract] [Full Text] [Related]

  • 18. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component.
    Bottazzi B, Vouret-Craviari V, Bastone A, De Gioia L, Matteucci C, Peri G, Spreafico F, Pausa M, D'Ettorre C, Gianazza E, Tagliabue A, Salmona M, Tedesco F, Introna M, Mantovani A.
    J Biol Chem; 1997 Dec 26; 272(52):32817-23. PubMed ID: 9407058
    [Abstract] [Full Text] [Related]

  • 19. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives.
    Leali D, Belleri M, Urbinati C, Coltrini D, Oreste P, Zoppetti G, Ribatti D, Rusnati M, Presta M.
    J Biol Chem; 2001 Oct 12; 276(41):37900-8. PubMed ID: 11473122
    [Abstract] [Full Text] [Related]

  • 20. The thymidine phosphorylase inhibitor 5'-O-tritylinosine (KIN59) is an antiangiogenic multitarget fibroblast growth factor-2 antagonist.
    Liekens S, Bronckaers A, Belleri M, Bugatti A, Sienaert R, Ribatti D, Nico B, Gigante A, Casanova E, Opdenakker G, Pérez-Pérez MJ, Balzarini J, Presta M.
    Mol Cancer Ther; 2012 Apr 12; 11(4):817-29. PubMed ID: 22302099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.